Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease

Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis

(2011) M. Arora et al.   BLOOD

Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation

(2011) Y. Inamoto et al.   BLOOD

Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease

(2011) K. J. Martires et al.   BLOOD

Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria

(2011) M. E. D. Flowers et al.   BLOOD

Allo-HLA-reactive T cells inducing graft-versus-host disease are single peptide specific

(2011) A. L. Amir et al.   BLOOD

Double cord blood transplantation: extending the use of unrelated umbilical cord blood cells for patients with hematological diseases

(2010) Vanderson Rocha et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma

(2010) G. R. Hill et al.   BLOOD

Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD

(2009) A. C. Vigorito et al.   BLOOD

Scleroderma

(2009) Armando Gabrielli et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cutaneous Chronic Graft-Versus-Host Disease Does Not Have the Abnormal Endothelial Phenotype or Vascular Rarefaction Characteristic of Systemic Sclerosis

(2009) Jo Nadine Fleming et al.   PLoS One

Clinical association of serum interleukin-17 levels in systemic sclerosis: Is systemic sclerosis a Th17 disease?

(2008) Maki Murata et al.   JOURNAL OF DERMATOLOGICAL SCIENCE